Literature DB >> 1532281

Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone.

J M Hock1, I Gera.   

Abstract

The role of resorption in the anabolic response of bone to parathyroid hormone (PTH) is not well understood. In contrast to the increase in bone mass induced by intermittent PTH in intact rats, continuous infusion of PTH into thyroparathyroidectomized (TPTX) rats failed to increase bone volume. The objective of this study were to determine if continuous infusions of low doses of PTH were anabolic in intact rats and if inhibition of resorption would enhance or block an anabolic action of PTH. Young male rats were treated with either continuous infusion or intermittent injections of hPTH-(1-34) for 12 days. In experiment 1, PTH, infused daily at 4 micrograms per 100 g, increased femur calcium and dry weight. Unlike infusion of 8 micrograms PTH, which did not alter bone mass, intermittent PTH at 8 micrograms was anabolic and increased bone mass by increasing trabecular thickness and number. Infusion of 16 micrograms induced hypercalcemia and death. In experiment 2, lower dose daily infusions of 0.25-4 micrograms PTH per 100 g did not increase bone mass. In experiment 3, in rats pretreated with dichloromethylene diphosphonate (Cl2MDP) to inhibit resorption and subsequently exhibiting decreased bone formation, PTH, irrespective of the method of administration, reversed the inhibitory effects of Cl2MDP on bone formation. Thus, intermittent and continuous PTH increase bone formation independently of effects on bone resorption, but only intermittent PTH increases bone mass consistently.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532281     DOI: 10.1002/jbmr.5650070110

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  86 in total

Review 1.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

2.  Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis.

Authors:  Peter E Daddona; James A Matriano; Jaap Mandema; Yuh-Fun Maa
Journal:  Pharm Res       Date:  2010-06-22       Impact factor: 4.200

3.  Modeled microgravity and hindlimb unloading sensitize osteoclast precursors to RANKL-mediated osteoclastogenesis.

Authors:  Ritu Saxena; George Pan; Erik D Dohm; Jay M McDonald
Journal:  J Bone Miner Metab       Date:  2010-06-30       Impact factor: 2.626

4.  Effects of continuous glucocorticoid infusion on bone metabolism in the rat.

Authors:  C S King; E C Weir; C W Gundberg; J Fox; K L Insogna
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

Review 5.  G Protein-coupled Receptor Biased Agonism.

Authors:  Sima Y Hodavance; Clarice Gareri; Rachel D Torok; Howard A Rockman
Journal:  J Cardiovasc Pharmacol       Date:  2016-03       Impact factor: 3.105

6.  Long-term stability and in vitro release of hPTH(1-34) from a multi-reservoir array.

Authors:  Elizabeth R Proos; James H Prescott; Mark A Staples
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

7.  Variation in the PTH2R gene is associated with age-related degenerative changes in the lumbar spine.

Authors:  Kristina Åkesson; Max Tenne; Paul Gerdhem; Holger Luthman; Fiona E McGuigan
Journal:  J Bone Miner Metab       Date:  2013-12-31       Impact factor: 2.626

8.  Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct.

Authors:  Robert Stratford; Christopher Vu; Joshua Sakon; Ranjitha Katikaneni; Robert Gensure; Tulasi Ponnapakkam
Journal:  J Pharm Sci       Date:  2014-01-07       Impact factor: 3.534

9.  Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study.

Authors:  Canan Tikiz; Hakan Tikiz; Fatma Taneli; Gül Gümüşer; Ciğdem Tüzün
Journal:  Clin Rheumatol       Date:  2005-03-02       Impact factor: 2.980

Review 10.  Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.

Authors:  Cristina Sobacchi; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Front Bioeng Biotechnol       Date:  2017-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.